Terns Pharmaceuticals Inc (TERN)
6.14
+0.15
(+2.50%)
USD |
NASDAQ |
May 16, 16:00
6.145
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals Cash from Financing (TTM): 14.37M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 14.37M |
December 31, 2023 | 41.95M |
September 30, 2023 | 134.06M |
June 30, 2023 | 195.04M |
March 31, 2023 | 194.68M |
December 31, 2022 | 167.10M |
September 30, 2022 | 61.14M |
Date | Value |
---|---|
June 30, 2022 | 0.937M |
March 31, 2022 | -0.776M |
December 31, 2021 | 134.39M |
September 30, 2021 | 203.02M |
June 30, 2021 | 202.25M |
March 31, 2021 | 220.72M |
December 31, 2020 | 85.52M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.776M
Minimum
Mar 2022
220.72M
Maximum
Mar 2021
118.17M
Average
134.23M
Median
Cash from Financing (TTM) Benchmarks
Viking Therapeutics Inc | 873.23M |
Eli Lilly and Co | 2.772B |
Pfizer Inc | 23.91B |
Amgen Inc | -2.169B |
Madrigal Pharmaceuticals Inc | 1.116B |